SynthesisFrontiers in oncology2021

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis.

Ye Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.